Shennon Biotechnologies
Immunotherapy
3 open rolesImmunotherapySan Francisco, United States16 employees$13M raisedEst. 2021
DCVC
Foundation Capital
AV8
Formulate Ventures
Future Ventures (San Francisco)
NextGen Venture Partners
About Shennon Biotechnologies
- Shennon Biotechnologies has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput.
- This technology aims to unlock key bottlenecks in immunotherapy and accelerate target discovery for more effective treatments for human diseases.
Shennon Biotechnologies is listed on Rocketlist with 3 active roles. The company is categorized as Immunotherapy in BioTech. Shennon Biotechnologies is at Seed stage, with a B2B business model, headquartered in San Francisco, United States. Shennon Biotechnologies was founded in 2021 and has 16 employees. Shennon Biotechnologies has raised $13M. Active roles are refreshed daily from public hiring sources.